August 18, 2014 | According to a “Globes” report, Novartis AG will acquire Gamida Cell, a developer of stem cell therapies including one for the treatment of blood cancer. The deal, which was previously called off, is back on, but will not involve an exit of millions of dollars and instead will occur in stages of investment from Novartis. Later in the process, Gamida Cell shareholders are expected to sell their holdings for a large sum. However, the deal still remains subject to the completion of Gamida Cell’s product NiCord, a blood cancer treatment. Gamida Cell is headed by CEO Dr. Yael Margolin.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Red Algae Can Treat Wounds And Infections
January 26, 2023

Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023

$6M Investment For “Lettuce Milk” Startup
January 25, 2023

Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments